Volume 2.05 | Feb 12

Immune Regulation News 2.05, February 12, 2010.
In this issue: Science News  |  Current Publications  |  Industry News  |  Policy News  |  Events Subscribe  |  Unsubscribe


HVCN1 Modulates B Cell Antigen Receptor Signal Strength via Regulation of B Cell Antigen Receptor-Dependent Generation of Reactive Oxygen Species
Researchers report here that the voltage-gated proton channel HVCN1 associated with the B cell antigen receptor (BCR) complex and was internalized together with the BCR after activation. [Nat Immunol]

Request A Poster  
Isolate Untouched Cells for
Antigen Processing and Presentation
with EasySep®


Video – EasySep® – Powerful Immunomagnetic Isolation of Virtually Any Cell Type


Scientists Identify Maternal and Fetal Genes that Increase Preterm Birth Risk
“A substantial body of scientific evidence indicates that inflammatory hormones may play a significant role in the labor process,” said Alan E. Guttmacher, M.D., acting director of the NIH’s Eunice Kennedy Shriver National Institute of Child Health and Human Development. “The current findings add evidence that individual genetic variation in that response may account for why preterm labor occurs in some pregnancies and not in others.” [Genetic Engineering and Biotechnology News]

How ‘Lipid Rafts’ Help Us Mount an Immune Response
Scientists have described the role of lipid rafts within the cascade of sub-microscopic events that help T cells survive and thrive. [Press release from Garvan Institute discussing online prepublication in Immunity

B Cells Promote Solid Tumor Formation – Another Use for Rituximab?
Using a mouse model of squamous carcinogenesis, researchers showed a functional role for B cells in defining a pro tumor microenvironment in premalignant tissue. [Press release from Gerson Lehrman Group discussing online prepublication in Cancer Cell]



Chromogranin A is an Autoantigen in Type 1 Diabetes
In the nonobese diabetic mouse model of type 1 diabetes, researchers have identified the peptide WE14 from chromogranin A as the antigen for highly diabetogenic CD4+ T cell clones. [Nat Immunol]

FcR(Gamma) Activation Regulates Inflammation-Associated Squamous Carcinogenesis
Using the K14-HPV16 mouse model of squamous carcinogenesis, researchers report that B cells and humoral immunity foster cancer development by activating Fc receptors on resident and recruited myeloid cells. [Cancer Cell]

Dependence of T Cell Antigen Recognition on T Cell Receptor-Peptide Major Histocompatibility Complex Confinement Time
Here, researchers analyze which binding properties of the T cell receptor-peptide-major histocompatibility (pMHC) complex interaction are responsible for this variation in pMHC activation potency. [Immunity]

T Cell Receptor-Dependent Regulation of Lipid Rafts Controls Naive CD8+ T Cell Homeostasis
T cell receptor contact with self ligands keeps T cells alive and is shown here to cause naive CD8+, but not CD4+, T cells to be hypersensitive to certain (gamma)c cytokines, notably interleukin (IL)-2, IL-15, and IL-7. [Immunity]
Foxp3+ T Cells Induce Perforin-Dependent Dendritic Cell Death in Tumor-Draining Lymph Nodes
Researchers showed the rejection of established ovalbumin (OVA)-expressing MCA101 tumors required both the adoptive transfer of OVA-specific CD8+ T cell receptor transgenic T cells and the neutralization of Foxp3+ T cells. [Immunity]

IL-7 and IL-15 Independently Program the Differentiation of Intestinal CD3-NKp46+ Cell Subsets from Id2-Dependent Precursors
Researchers investigated the developmental relationships between intestinal CD3-NKp46+ cellular subsets. [J Exp Med]

Implication of the CD47 Pathway in Autoimmune Diabetes
Using a T cell receptor transgenic mouse model at the brink of autoimmune disease, researchers demonstrate that CD47-deficiency is sufficient to break the immune tolerance and provoke the onset of autoimmune diabetes. [J Autoimmun]

Foxp3 Induction in Human and Murine Thymus Precedes the CD4+CD8+ Stage but Requires Early T Cell Receptor Expression
By analyzing a large collection of 21 human thymuses, researchers show that Foxp3 can be consistently detected in CD4 immature single positive thymocytes that precede the CD4+CD8+ (double positive) stage. [Immunol Cell Biol]

Naturally Occurring Tumor-Specific CD8+ T Cell Precursors in Individuals With and Without Cancer
This study was scheduled to determine possible differences in the frequency and the function of naturally occurring cytolytic CD8+ T cell precursors against multiple peptides derived from the cancer-testis antigens MAGE-A1 and MAGE-A3, and the overexpressed antigen hTERT, in newly diagnosed lung cancer patients as compared with aged-matched healthy individuals. [ Immunol Cell Biol]

Potent Anti-Tumor Responses to Immunization with Dendritic Cells Loaded with Tumor Tissue and an Natural Killer-Like T Cell Ligand
To enhance anti-tumor CD8+ T cell responses induced by immunization with antigen-loaded dendritic cells, researchers explored the impact of eliciting a potent source of T cell help from activated invariant natural killer-like T cells using the specific glycolipid ligand ??-galactosylceramide. [Immunol Cell Biol]

Influenza Viruses Differ in Ability to Infect Macrophages and to Induce a Local Inflammatory Response Following Intraperitoneal Injection of Mice
Given the central role of murine macrophages in initiating and regulating inflammatory responses, researchers hypothesized that virus strains that infect murine macrophages poorly may also be poor at initiating inflammatory responses. [Immunol Cell Biol]



TenX Biopharma Licenses Zanolimumab from Genmab
TenX Biopharma, Inc. announced that it has signed a licensing agreement to acquire exclusive worldwide rights to develop and commercialize zanolimumab (HuMax-CD4®) from Genmab A/S. [TenX Biopharma, Inc. Press Release]

MedNet Solutions Deploys Global Peripheral T Cell Lymphoma Registry for Allos Therapeutics
MedNet Solutions has announced that Allos Therapeutics’ new international disease-specific registry for patients with peripheral T cell lymphoma has enrolled its first study participant. [PR Newswire]

Micromet Highlights Clinical Plans and Regulatory Strategy for Lead Product Candidate Blinatumomab at its Annual R&D Day
At its annual investor R&D day, Micromet, Inc. outlined the design of a registration study for the Company’s lead product candidate blinatumomab in acute lymphocytic leukemia, highlighted clinical data demonstrating the breadth of blinatumomab’s activity in B cell non-Hodgkin’s lymphomas and announced plans to expand clinical development of blinatumomab in the U.S. [Micromet Press Release]

Exploratory Data Presented for Active Biotech’s ANYARA Project
Active Biotech has presented results from exploratory preclinical studies at the Keystone Symposia “Molecular and Cellular Biology of Immune Escape in Cancer” held in Keystone, Colorado, USA, February 7-12. [Active Biotech Press Release]

Inovio Biomedical Cervical Cancer Therapeutic Vaccine Generates Dose-Related Immune Response in Clinical Trial
Inovio Biomedical Corporation, a leader in DNA vaccine design, development and delivery, announced additional interim safety and immunogenicity data from its therapeutic cervical cancer vaccine (VGX-3100) trial. [Inovio Biomedical Corporation Press Release]


Parsing National Institutes of Health’s 2011 Budget: Is Big Science Up, Small Science Down?
Is National Institutes of Health Director Francis Collins planning to steer his ocean liner of an institute toward “big biology” at the expense of single-investigator grants? [National Institutes of Health, United States]

Medvedev Talks Science in Moscow
Russian science has been getting some bad press recently, what with a recent report on its declining productivity in scientific papers and a letter from expatriate scientists to the Russian president and prime minister warning of the parlous state of basic research. [Russian Academy of Sciences, Russia]

Impersonation of MHRA Staff [Medicines and Healthcare Products Regulatory Agency, United Kingdom]

Waivers for Conflicts of Interest for the February 22, 2010 Vaccines and Related Biological Products Advisory Committee Meeting [Center for Biologics Evaluation and Research, United States]

Recovery Act Limited Competition: Program to Enhance National Institutes of Health-Supported Global Health Research Involving Human Subjects (S07) (RFA-OD-10-006) [National Institutes of Health, United States]

Institutional Clinical and Translational Science Award (U54) (RFA-RM-10-001) [National Institutes of Health, United States]

IACUC 101 Workshop and PRIM&R 2010 IACUC Conference: March 21-23, 2010 in Baltimore, MD (NOT-OD-10-059) [National Institutes of Health, United States]

Delays in Grant Application Submission Due to Blizzard (NOT-OD-10-060) [National Institutes of Health, United States]

Notice of Intent to Establish a New National Institutes of Health Common Fund Program: Library of Integrated Network-Based Cellular Signatures (LINCS) (NOT-RM-10-002) [National Institutes of Health, United States]

Notice of Availability of Administrative Supplements for R25 Science Education Grants (NOT-DA-10-007) [National Institutes of Health, United States]

Investigator Initiated Multi-Site Clinical Trials (Collaborative R01) (PAR-10-096) [National Heart, Lung, and Blood Institute, United States]


Keystone Symposia: Tolerance and Autoimmunity (B7)
February 21-26, 2010
Taos, United States

American Academy of Allergy, Asthma & Immunology (AAAAI)
February 26-March 2, 2010
New Orleans, United States

Keystone Symposia: Lymphocyte Activation and Gene Expression (B8)
February 27-March 4, 2010
Breckenridge, United States

World Immune Regulation Meeting (WIRM) – IV
March 29-April 01, 2010
Davos, Switzerland

American Association for Cancer Research (AACR) 101st Annual Meeting 2010
April 17-21, 2010
Washington, DC, United States

23rd Annual Canadian Society for Immunology (CSI) Conference
April 23-26, 2010
Niagara Falls, Canada

97th Annual Meeting of the American Association of Immunologists
May 7-11, 2010
Baltimore, United States

29th Congress of the European Academy of Allergy and Clinical Immunology (EAACI)
June 5-9, 2010
London, United Kingdom

Keystone Symposia: Innate Immunity: Mechanisms Linking with Adaptive Immunity (D3)
June 7-12, 2010
Dublin, Ireland

Federation of Clinical Immunology Societies (FOCIS) 2010
June 24-27, 2010
Boston, United States

Frontiers in Immunology Research (FIRN) 2010 International Conference
July 22-26, 2010
Athens, Greece

14th International Congress of Immunology
August 22-27, 2010
Kobe, Japan

Visit our events page to stay up to date with the latest events in the cell, gene and immunotherapy community.



Business Development Europe – Cell Therapy Products (PALL Corporation)

Recruit Top Talent
Reach more than 11,000 potential candidates by posting your organization’s career opportunities with Cell Therapy News.

Visit here to post your career opportunities.

Have we missed an important article or publication in Immune Regulation News? Click here to submit!


Learn more about Immune Regulation News: Archives  |  Events  |  Subscribe  |  Contact Us